Cingulate inc.CING.US Overview

US StockHealthcare

(No presentation for CING)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

CING Overall Performance

CING AI Analysis & Strategy

CING Recent Performance

0.21%

Cingulate inc.

1.30%

Avg of Sector

0.61%

S&P500

CING PowerScanner

CING Key Information

CING Valuation Metrics

CING Earnings Table

CING Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.